Lila Sciences closes $350m series A to expand AI science platform
US biotech startup Lila Sciences has closed its series A at $350 million, lifting its total fundraising to $550 million. The latest capital will accelerate the company’s plans to expand its AI science factories and make its platform available to customers tackling complex scientific challenges.
The financing, completed in two parts, adds NVentures, the venture arm of Nvidia (Nasdaq: NVDA), along with Analog Devices (Nasdaq: ADI), IQT and others including Flagship Pioneering, where Lila was founded.
Chief executive Geoff von Maltzahn said: “This capital raise of $550 million across Lila’s seed and Series A will accelerate Lila across these core areas: superhuman scientific performance, scaling up AI science factories, opening the platform to commercial partners, and adding more of the world’s most brilliant minds to our mission.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze